PCI Synthesis Announces Successful FDA inspection and Pre-Approval of Two Products

Brings the company's total to eight active pharmaceutical ingredients (APIs) to receive Pre-Approval/Commercial status

Posted: September 18, 2013

API Manufacturing and Pharmaceutical Manufacturing

PCI Synthesis, Inc. (www.pcisynthesis.com), a custom chemical manufacturer of new chemical entities (NCE), generic active pharmaceutical ingredients (API), and other specialty chemical products, announced the completion of the sixth inspection of the company’s cGMP site in Newburyport, MA by the FDA.

During the multi-week inspection, the FDA conducted a general cGMP compliance review as well as Pre-Approval Inspections (PAIs) for two active pharmaceutical ingredients (APIs) filed by two different clients earlier this year. PCI now has a total of eight products that have been successfully Pre-Approved and/or commercialized to date.

PCI, which provides small and mid-sized companies with the expertise to manufacture complex small molecules to be used as active pharmaceutical ingredients (APIs), currently has four new chemical entities in clinical development that were recently included in the “Top 50 Drugs in Development to Watch” list.  In addition, over the past two years, PCI has launched more than five new proprietary APIs for the generic market with exclusive supply agreements – bringing its total to 17 exclusive APIs in its overall pipeline.

“Everyone at PCI is continuously working to improve the quality systems throughout our organization.  Our efforts and investments in our facilities, training and new technologies, have been validated by another successful FDA inspection.  More than that, the latest PAI pre-approvals further substantiate that our team understands the complex dynamics of small molecule development, including manufacturing, process optimization, scale up and comprehensive analytical support,” said Edward S. Price, President of PCI Synthesis.  “The focus on product approvals and approved APIs is part of our commitment to full scale R&D, which further positions PCI as an innovative CMO.”

About PCI Synthesis

PCI Synthesis is a 15-year-old custom chemical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products.  A contract manufacturing organization (CMO), PCI provides small and mid-sized companies with expertise needed to manufacture complex small molecules to be used in both the branded and generic market.  To learn more about PCI Synthesis, its proprietary APIs, and R&D, please visit www.pcisynthesis.com.

Related posts:

New England CRO/CMO Council to Hold Town Hall Meeting and Discussion
Meeting time and cost challenges to accelerate drug development addressed in Inaugural MassBio sympo...
PCI Synthesis Identifies Trends Affecting the Generic Drugs Sector in 2017
Scott VanderWel Joins PCI Synthesis as Business Development Manager
PCI Synthesis’ Ed Price Joins SOCMA’s Board of Governors

About the Author

Ed Price CEO of PCI Synthesis
Ed is the President and CEO of PCI Synthesis (PCI), he serves as a co-chair of the New England CRO/CMO Council and sits on the Industrial Advisory Board for the Department of Chemical Engineering at UMass, Amherst. Ed is also a long standing member of the American Chemical Society and advises the Bulk Pharmaceutical Task Force of the Society of Chemical Manufacturer’s and Affiliates (SOCMA).

Do you have questions? Talk to Ed.